Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biophytis ( (BPTSY) ) just unveiled an update.
On May 30, 2025, Biophytis announced the postponement of its 2024 annual financial statements due to technical complications in the audit process. The company aims to publish the statements by the end of June 2025 and has also delayed its Ordinary General Meeting of shareholders, coordinating with the Paris Commercial Court. This delay may impact stakeholders’ expectations and the company’s operational timeline.
The most recent analyst rating on (BPTSY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101 (20-hydroxyecdysone), is being developed for muscular diseases such as sarcopenia and metabolic disorders like obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis’ ordinary shares are listed on Euronext Growth Paris and its ADS on the OTC market.
Average Trading Volume: 25
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.03M
Learn more about BPTSY stock on TipRanks’ Stock Analysis page.